Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00334-0/fulltext